Évaluation d'un modèle différencié de recherche et de gestion active des cas au point de service pour éliminer la transmission mère-enfant du VIH au Malawi (PAC-Man)
UNCPM 22401 - Évaluation d'un modèle différencié de recherche et de gestion active des cas au point de service pour l'élimination de la transmission mère-enfant du VIH à Lilongwe et Mangochi, Malawi
Purpose: To conduct a hybrid effectiveness-implementation stepped-wedge trial to:
- Estimate the effect of the PAC-Man model, compared to SOC, on the proportion of infants who receive timely EID testing.
- Estimate the effect of the PAC-Man model, compared to SOC, on the proportion of pregnant and breastfeeding women living with HIV who receive guideline-adherent viral load testing.
- Compare implementation outcomes between the PAC-Man model and SOC.
Participants: The total study sample size is 2,426, including 2,304 mother-infant pair (MIP) survey participants, 48 high-risk pregnant/breastfeeding women living with HIV for in-depth interviews (from high-risk MIPs who participated in a survey); 10 PMTCT policy makers and Ministry of Health (MOH)/ President's Emergency Plan for AIDS Relief (PEPFAR) implementing partner senior managers for key informant interviews; and about 48-64 professional and lay health providers for focus group discussions and implementation actor surveys.
To rigorously evaluate the PAC-Man model, investigators will use a hybrid (type 3) effectiveness-implementation incomplete stepped-wedge trial design. The hybrid incomplete stepped-wedge design is a rigorous quasi-experimental design that allows for incremental "rollout" of the PAC-Man model and serial measurement of both health outcomes (for infants and mothers in Objectives 1 and 2, respectively), as well as implementation outcomes (Objective 3). The incomplete stepped-wedge design is more efficient than a complete design, minimizes costs, and reduces participant burden, without sacrificing statistical precision. Using this design, sequential crossover from control (i.e., the SOC) to intervention (i.e., SOC plus the PAC-Man model) takes place at each 'step' using cluster randomization until all clusters (defined as a group of "sites," or health facilities plus the surrounding communities in its catchment area) receive the intervention. The 12 sites included in our study will be divided into 4 clusters of 3 sites each.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
PAC-Man Model:
PAC-Man represents an integrated differentiated services delivery (DSD) model for mothers and infants that brings the following three evidence-based practices into the community for elimination of mother to child transmission (EMTCT): 1) pediatric active case finding using novel point-of-care (POC) early infant diagnosis (EID) technology; 2) same-day antiretroviral therapy (ART) initiation for infants newly diagnosed with HIV infection; and 3) maternal viral load (mVL) testing and back-to-care services. PAC-Man uses a mobile approach to offer EMTCT services in the community and reach "high risk" MIPs in which the mother living with HIV did not initiate ART, started ART late during pregnancy or breastfeeding, dropped off treatment following ART initiation, was unsuppressed on ART, was identified with HIV infection for the first-time during the post-partum period, and/or did not return with her infant for EID testing. Because these evidence-based practices are already recommended by the Ministry of Health and will be functioning at the site and not the individual level, delivering the PAC-Man model will be done under the auspices of routine care, applying an overarching implementation strategy of creating new mobile care teams equipped with new diagnostic technology who deploy the m-PIMA™ in community settings.
PAC-Man Implementation Approaches:
The overall implementation strategy being evaluated in this study is the creation of mobile care teams to deploy m-PIMA™ and provide EMTCT services in the community. Complementing this overarching strategy will be two sub-strategies used to enhance PAC-Man adoption: 1) task shifting of active case finding, EID and mVL testing, ART initiation, and back-to-care services to community health workers (CHWs), community nurses, and HIV diagnostic assistants; and 2) changing service sites to convenient locations in the community to overcome barriers to EID and mVL delivery. These strategies are intended to work in concert with the above evidence-based practices to integrate PAC-Man into the EMTCT program.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Michael Herce, MD, MPH
- Numéro de téléphone: 9198435996
- E-mail: michael_herce@med.unc.edu
Lieux d'étude
-
-
-
Lilongwe, Malawi
- Recrutement
- Area 18 Health Centre
-
Contact:
- Chimwemwe Kumwenda
- Numéro de téléphone: +265-999-265626
- E-mail: ckumwenda@unclilongwe.org
-
Monkey Bay, Malawi
- Recrutement
- Monkey Bay Community Hospital
-
Contact:
- Chimwemwe Kumwenda
- Numéro de téléphone: +265-999-265626
- E-mail: ckumwenda@unclilongwe.org
-
-
Central Region
-
Lilongwe, Central Region, Malawi
- Pas encore de recrutement
- Bwaila Hospital
-
Contact:
- Michael Herce, MD, MPH
- Numéro de téléphone: 9198435996
- E-mail: michael_herce@med.unc.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
The criteria for Enumerated MIP Cohort is as follows:
Inclusion Criteria:
- Enrolled in the national EMTCT program at a study site in the 12 months preceding a survey.
Exclusion Criteria:
- None.
The criteria for Enumerated MIP Field Survey is as follows:
Inclusion Criteria:
- Age 16 years or older.
- Enrolled in the national EMTCT program at a study site in the 12 months preceding a survey.
Exclusion Criteria:
- Documented transferred out from a site prior to the field survey.
- Participated previously in the field survey.
- Decline informed consent.
The criteria for In-Depth Interviews is as follows:
Inclusion criteria:
- Age 16 years or older.
- Met high-risk criteria for PAC-Man model.
- Participated in a field survey.
Exclusion criteria:
- Decline informed consent.
The criteria for Focus Group Discussions is as follows:
Inclusion criteria:
- Age 18 years or older.
- MOH or implementing partner professional or lay health worker at a study site (such as nurses, community health workers, health surveillance assistants, and HIV diagnostic assistants)
- Generally familiar with the PAC-Man model and/or EMTCT/ EID service delivery at their site.
Exclusion criteria:
- Decline informed consent.
The criteria for Key Informant Interviews is as follows:
Inclusion criteria:
- Age 18 years or older.
- HIV/ EMTCT policy maker OR MOH/ PEPFAR implementing partner senior manager.
- Generally familiar with HIV and/or EMTCT/ EID service delivery.
Exclusion criteria:
- Decline informed consent.
The criteria for Implementation Actor Questionnaires is as follows:
Inclusion criteria:
- Age 18 years or older.
- Professional or lay health provider at a study site.
- Generally familiar with HIV and/or EMTCT/ EID service delivery at their site.
- Participated in a focus group discussion.
Exclusion criteria:
- Decline informed consent.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: PAC-Man Model
PAC-Man represents an integrated DSD model for mothers and infants that brings the following three evidence-based practices into the community for EMTCT: 1) pediatric active case finding using novel POC EID technology; 2) same-day ART initiation for infants newly diagnosed with HIV infection; and 3) mVL testing and back-to-care services. PAC-Man uses a mobile approach to offer EMTCT services in the community and reach "high risk" MIPs. Delivering the PAC-Man model will be done under the auspices of routine care, applying an overarching implementation strategy of creating new mobile care teams equipped with new diagnostic technology who deploy the m-PIMA in community settings. |
PAC-Man represents an integrated DSD model for mothers and infants that brings the following three evidence-based practices into the community for EMTCT: 1) pediatric active case finding using novel POC EID technology; 2) same-day ART initiation for infants newly diagnosed with HIV infection; and 3) mVL testing and back-to-care services. PAC-Man uses a mobile approach to offer EMTCT services in the community and reach "high risk" MIPs. Delivering the PAC-Man model will be done under the auspices of routine care, applying an overarching implementation strategy of creating new mobile care teams equipped with new diagnostic technology who deploy the m-PIMA in community settings. |
|
Comparateur actif: Standard of care (control arm)
Routine care as provided by the Ministry of Health. |
Routine care as provided by Ministry of Health. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of infants who receive EID testing by age 6 months
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants exposed to HIV who receive EID testing by age 6 months among the enumerated cohort of MIPs with infants at least 6 weeks old at all study sites. |
Within 12 months of MIP enrollment in the national EMTCT program
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of infants who receive EID testing by age 2 months
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants exposed to HIV who receive EID testing by age 2 months among the enumerated cohort of all MIPs with infants at least 6 weeks old at all study sites. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of infants who receive EID testing by age 12 months
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants exposed to HIV who receive EID testing by age 12 months among the enumerated cohort of all MIPs with infants at least 6 weeks old at all study sites. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of high-risk infants who receive EID testing by age 6 months
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants with high-risk mothers exposed to HIV who receive EID testing by age 6 months among all high-risk MIPs with infants at least 6 weeks old at all study sites. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of infants who initiate ART
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants newly diagnosed with HIV who initiate ART ≤60 days from EID sample collection among the enumerated cohort of all infants. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Median infant results return time
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Median number of days from infant EID sample collection to results returned to caregivers. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of infants newly diagnosed with HIV
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants newly diagnosed with HIV among the enumerated cohort of all infants. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Median age at ART initiation among infants
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Median age in months at ART initiation among infants who test positive for HIV. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Median time to ART initiation among infants
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Median number of days to ART initiation among infants who test positive for HIV. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of infants who initiate ART the same day as diagnosis
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants newly diagnosed with HIV who initiate ART on the same day as EID results received among the enumerated cohort of all infants. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of infants with HIV retained in care at 3 months post-ART initiation
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants with HIV who are retained in care at 3-months post-ART initiation. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of infants with HIV retained in care at 6 months post-ART initiation
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants with HIV who are retained in care at 6-months post-ART initiation. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of MIPs reached with viral load testing
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of mothers living with HIV who received MOH-recommended 6-monthly VL testing during pregnancy and breastfeeding among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of high-risk MIPs reached with viral load testing
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of high-risk MIPs living with HIV who received MOH-recommended 6-monthly VL testing during pregnancy and breastfeeding among all high-risk MIPs from the enumerated cohort. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of MIPs virally suppressed at 6 months
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of mothers with viral suppression (<1,000 copies of HIV per ml.) at 6 months after EMTCT enrollment among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of high-risk MIPs virally suppressed at 6 months
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of high-risk mothers with viral suppression (<1,000 copies of HIV per ml.) at 6 months after EMTCT enrollment among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of MIPs virally suppressed at 12 months
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of mothers with viral suppression (<1,000 copies of HIV per ml.) at 12 months after EMTCT enrollment among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of high-risk MIPs virally suppressed at 12 months
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of high-risk mothers with viral suppression (<1,000 copies of HIV per ml.) at 12 months after EMTCT enrollment among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of MIPs retained in care at 6 months
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of mothers who are retained in care (≥1 clinic encounter within the last 180 days) at 6 months after EMTCT enrollment among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of MIPs retained in care at 12 months
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of mothers who are retained in care (≥1 clinic encounter within the last 180 days) at 12 months after EMTCT enrollment among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of MIPs who resumed ART
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of mothers who had documented treatment interruption (i.e., a treatment gap ≥28 days) who later resumed ART among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of MIPs who received enhanced adherence counseling
Délai: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of MIPs who had unsuppressed viral load and then completed enhanced adherence counselling among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Adoption - proportion of sites that adopt the PAC-Man model
Délai: 6-12 months after sites switch to intervention; study endline (Approximately 12 months from the time that last study sites are switched to the intervention)
|
Number of trained sites that deliver the PAC-Man intervention divided by the total number of trained sites. Study endline sustainability survey is conducted at the end of the trial once all study sites have been randomized to receive the intervention. |
6-12 months after sites switch to intervention; study endline (Approximately 12 months from the time that last study sites are switched to the intervention)
|
|
Adoption - proportion of providers who adopt the PAC-Man model
Délai: 6-12 months after sites switch to intervention; study endline (Approximately 12 months from the time that last study sites are switched to the intervention)
|
Number of trained providers who deliver the PAC-Man intervention divided by the total number of trained providers. Study endline sustainability survey is conducted at the end of the trial once all study sites have been randomized to receive the intervention. |
6-12 months after sites switch to intervention; study endline (Approximately 12 months from the time that last study sites are switched to the intervention)
|
|
Implementation - cost per pediatric case
Délai: 6-12 months after sites switch to intervention; study endline (Approximately 12 months from the time that last study sites are switched to the intervention)
|
Incremental cost of PAC-Man implementation per pediatric HIV case identified, compared to standard of care. Study endline sustainability survey is conducted at the end of the trial once all study sites have been randomized to receive the intervention. |
6-12 months after sites switch to intervention; study endline (Approximately 12 months from the time that last study sites are switched to the intervention)
|
|
Implementation - cost per unsuppressed MIP
Délai: 6-12 months after sites switch to intervention; study endline (Approximately 12 months from the time that last study sites are switched to the intervention)
|
Incremental cost of PAC-Man implementation per pregnant and breastfeeding woman with unsuppressed viral load identified, compared to standard of care. Study endline sustainability survey is conducted at the end of the trial once all study sites have been randomized to receive the intervention. |
6-12 months after sites switch to intervention; study endline (Approximately 12 months from the time that last study sites are switched to the intervention)
|
Collaborateurs et enquêteurs
Collaborateurs
Les enquêteurs
- Chercheur principal: Michael Herce, MD, MPH, University of North Carolina, Chapel Hill
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 24-0561
- 1P01HD112215 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with The University of North Carolina at Chapel Hill (UNC).
Délai de partage IPD
Beginning 9 and continuing for 36 months following publication
Critères d'accès au partage IPD
Investigator has approved IRB, IEC, or REB and an executed data use/sharing agreement with UNC.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .